The short version of TB-500 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-14. Anything still debated is marked as such rather than presented as settled.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Researchers in the National Center for Nanoscience and Technology in Beijing and Arizona State University reported a DNA origami delivery vehicle for Doxorubicin, a well-known anti-cancer drug. The drug was non-covalently attached to DNA origami nanostructures through intercalation and a high drug load was achieved. The DNA-Doxorubicin complex was taken up by human breast adenocarcinoma cancer cells (MCF-7) via cellular internalization with much higher efficiency than doxorubicin in free form. The enhancement of cell killing activity was observed not only in regular MCF-7, more importantly, also in doxorubicin-resistant cells. The scientists theorized that the doxorubicin-loaded DNA origami inhibits lysosomal acidification, resulting in cellular redistribution of the drug to action sites, thus increasing the cytotoxicity against the tumor cells. Further testing on in vivo on mice suggests that over a 12-day period, Doxorubicin was more effective at reducing tumor sizes in mice when it was contained in DNA origami nanostructures (DONs). Researchers from the Massachusetts Institute of Technology are developing a method to attach various viral antigens to Virus-shaped DNA particles to mimic the virus to be used to develop new vaccines. This was started in 2016 when Bathe's lab created an algorithm known as DAEDALUS (DNA Origami Sequence Design Algorithm for User-defined Structures) to generate precision-controlled three-dimensional shapes of DNA.
Chinese premier Wen Jiabao apologised to the nation, saying he felt "extremely guilty" about the poisoned milk products, in the same way he had previously asked the people's pardon for the deaths of coal miners, polluted drinking water, and train passengers stranded by the authorities' inadequate response to the severe snowstorm during the New Year.
(CH3)2CHC(O)CO2− + CH2O → HOCH2(CH3)2CC(O)CO2− This conversion is catalyzed by ketopantoate hydroxymethyltransferase. Like many α-ketoacids, α-ketoisovaleric acid is prone to decarboxylation to give isobutyraldehyde:
The State recognises the special position of the Holy Catholic Apostolic and Roman Church as the guardian of the Faith professed by the great majority of the citizens. The State also recognises the Church of Ireland, the Presbyterian Church in Ireland, the Methodist Church in Ireland, the Religious Society of Friends in Ireland, as well as the Jewish Congregations and the other religious denominations existing in Ireland at the date of the coming into operation of this Constitution. Following a referendum, this section was removed in 1973. After the setting up of the Free State in 1923, unionism in the south largely came to an end. The 1937 Constitution saw a notable ideological slant to the changes in the framework of the State in such a way as to create one that appeared to be distinctly Irish. This was done by implementing corporatist policies (based on the concepts of the Roman Catholic Church, as Catholicism was perceived to be deeply embedded with the perception of Irish identity). A clear example of this is the model of the reconstituted Seanad Éireann (the Senate), which operates based on a system of vocational panels, along with a list of appointed nominating industry bodies, a corporatist concept (seen in Pope Pius XI's 1931 encyclical Quadragesimo anno). Furthermore, Ireland's main political parties, Fine Gael, Fianna Fáil and Labour, all had an inherently corporatist outlook. The government was the subject of intense lobbying by leading Church figures throughout the 1930s in calling for reform of the State's framework.
FAD-dependent proteins function in a large variety of metabolic pathways including electron transport, DNA repair, nucleotide biosynthesis, beta-oxidation of fatty acids, amino acid catabolism, as well as synthesis of other cofactors such as CoA, CoQ and heme groups. One well-known reaction is part of the citric acid cycle (also known as the TCA or Krebs cycle); succinate dehydrogenase (complex II in the electron transport chain) requires covalently bound FAD to catalyze the oxidation of succinate to fumarate by coupling it with the reduction of ubiquinone to ubiquinol. The high-energy electrons from this oxidation are stored momentarily by reducing FAD to FADH2. FADH2 then reverts to FAD, sending its two high-energy electrons through the electron transport chain; the energy in FADH2 is enough to produce 1.5 equivalents of ATP by oxidative phosphorylation. Some redox flavoproteins non-covalently bind to FAD like Acetyl-CoA-dehydrogenases which are involved in beta-oxidation of fatty acids and catabolism of amino acids like leucine (isovaleryl-CoA dehydrogenase), isoleucine, (short/branched-chain acyl-CoA dehydrogenase), valine (isobutyryl-CoA dehydrogenase), and lysine (glutaryl-CoA dehydrogenase). Additional examples of FAD-dependent enzymes that regulate metabolism are glycerol-3-phosphate dehydrogenase (triglyceride synthesis) and xanthine oxidase involved in purine nucleotide catabolism.
Sources: en.wikipedia.org
Addiction is a serious risk with heavy recreational amphetamine use, but is unlikely to occur from long-term medical use at therapeutic doses; in fact, lifetime stimulant therapy for ADHD that begins during childhood reduces the risk of developing substance use disorders as an adult. Pathological overactivation of the mesolimbic pathway, a dopamine pathway that connects the ventral tegmental area to the nucleus accumbens, plays a central role in amphetamine addiction. Individuals who frequently self-administer high doses of amphetamine have a high risk of developing an amphetamine addiction, since chronic use at high doses gradually increases the level of accumbal ΔFosB, a "molecular switch" and "master control protein" for addiction. Once nucleus accumbens ΔFosB is sufficiently overexpressed, it begins to increase the severity of addictive behavior (i.e., compulsive drug-seeking) with further increases in its expression. While there are currently no effective drugs for treating amphetamine addiction, regularly engaging in sustained aerobic exercise appears to reduce the risk of developing such an addiction. Exercise therapy improves clinical treatment outcomes and may be used as an adjunct therapy with behavioral therapies for addiction.
== Cherenkov counting == High-energy beta emitters, such as phosphorus-32 and yttrium-90 can also be counted in a scintillation counter without the cocktail, instead using an aqueous solution containing no scintillators. This technique, known as Cherenkov counting, relies on Cherenkov radiation being detected directly by the photomultiplier tubes. Cherenkov counting benefits from the use of plastic vials which scatter the emitted light, increasing the potential for light to reach the photomultiplier tube.
The mean improvement in scores with dextromethorphan/bupropion was statistically significant but not clinically significant relative to placebo at all assessed timepoints including at the end of week 1, although at the end of the study some patients did have clinically significant improvement. In Study 2 (STRIDE-1), dextromethorphan/bupropion was compared with bupropion alone in another randomized controlled trial. The dose of bupropion in the study was lower than the target dose recommended for clinical practice. In this study, dextromethorphan/bupropion showed significantly greater improvement than bupropion alone in the first two weeks of treatment but not by week 6 of treatment in people with major depressive disorder. The baseline scores were 33.4 points with dextromethorphan/placebo and 33.2 points with placebo, while the score reductions at week 1 were 5.2 points on the MADRS with dextromethorphan/bupropion and 3.6 points with bupropion (a 1.6-point difference), at week 2 were 8.0 points with dextromethorphan/bupropion and 6.1 points with bupropion (a 1.9-point difference), and at week 6 were 11.6 points with dextromethorphan/bupropion and 9.4 points with bupropion (a 2.2-point difference). On the basis of this trial, the FDA concluded that dextromethorphan contributes to the apparent antidepressant effects of dextromethorphan/bupropion.
== Research and academic contributions == Eke's research focuses on optimizing the safe and effective use of medications in pregnancy and lactation. His work spans pharmacokinetics, pharmacodynamics, pharmacoepidemiology, pharmacogenomics, and pharmacometrics. He has led clinical and translational research on drug safety, dosing, and interactions in pregnant women, particularly in relation to preterm birth, HIV, hepatitis C, tuberculosis, sickle cell disease, hypertensive disorders of pregnancy, and substance use disorders. His studies integrate approaches such as longitudinal cohort designs, intensive and sparse pharmacokinetic sampling, population-based modeling, physiologically based pharmacokinetic modelling, and real-world data analysis. He has pioneered the use of high-dimensional omics such as proteomics and metabolomics in investigating the pathophysiology of complex pregnancy-related conditions. This work contributes to the development of personalized pharmacotherapy strategies and regulatory guidance for medication use during pregnancy. Eke has received multiple research grants from the NIH, including a Women's Reproductive Health Research (WRHR) Career Development award, a K23 Career Development award, and a National Institutes of Health Director's Pioneer Award (DP1), which supports innovative and high-impact research.
Sources: en.wikipedia.org
=== tip-tis === tipapkinogene sovacivec (INN) tipelukast (USAN) tipentosin (INN) tipepidine (INN) tipetropium bromide (INN) tipifarnib (USAN) tipindole (INN) tiplasinin (USAN) tiplimotide (INN) tipredane (INN) tiprelestat (INN) tiprenolol (INN) tiprinast (INN) tiprolisant (USAN) tipropidil (INN) tiprostanide (INN) tiprotimod (INN) TipTapToe tiqueside (INN) tiquinamide (INN) tiquizium bromide (INN) tiracizine (INN) tirapazamine (INN) tiratricol (INN) tirilazad (INN) tirofiban (INN) tiropramide (INN) tirzepatide (INN) Tis-U-Sol tisagenlecleucel (USAN, INN) Tiseb Tisit tislelizumab (INN) tisocalcitate (USAN) tisocromide (INN) tisopurine (INN) tisoquone (INN) Tissueblue Titralac
These diseases can be difficult to diagnose due to the close relation of the musculoskeletal system to other internal systems. The musculoskeletal system refers to the system having its muscles attached to an internal skeletal system and is necessary for humans to move to a more favorable position. Complex issues and injuries involving the musculoskeletal system are usually handled by a physiatrist (specialist in physical medicine and rehabilitation) or an orthopaedic surgeon.
=== Other complications === Compartment syndrome is treated with surgery to relieve the pressure inside the muscle compartment and reduce the risk of compression on blood vessels and nerves in that area. Fasciotomy is the incision of the affected compartment. Often, multiple incisions are made and left open until the swelling has reduced. At that point, the incisions are closed, often requiring debridement (removal of non-viable tissue) and skin grafting in the process. The need for fasciotomy may be decreased if mannitol is used, as it can relieve muscle swelling directly. Disseminated intravascular coagulation generally resolves when the underlying causes are treated, but supportive measures are often required. For instance, if the platelet count drops significantly and there is resultant bleeding, platelets may be administered.
On the bicentenary of its foundation, the British newspaper The Guardian, reflecting on its major errors of judgment, included the support the paper's editor, C. P. Scott, gave to Balfour's declaration. Israel had not become, it said, 'the country the Guardian foresaw or would have wanted.' The Board of Deputies of British Jews through its president Marie van der Zyl denounced the column as 'breathtakingly ill-considered', declaring that the Guardian appeared "to do everything it can to undermine the legitimacy of the world's only Jewish state".
MRI requires a magnetic field that is both strong and uniform to a few parts per million across the scan volume. The field strength of the magnet is measured in teslas – and while the majority of systems operate at 1.5 T, commercial systems are available between 0.2 and 7 T. 3T MRI systems, also called 3 Tesla MRIs, have stronger magnets than 1.5 systems and are considered better for images of organs and soft tissue. Whole-body MRI systems for research applications operate in e.g. 9.4T, 10.5T, 11.7T. Even higher field whole-body MRI systems e.g. 14 T and beyond are in conceptual proposal or in engineering design. Most clinical magnets are superconducting magnets, which require liquid helium to keep them at low temperatures. Lower field strengths can be achieved with permanent magnets, which are often used in "open" MRI scanners for claustrophobic patients. Lower field strengths are also used in a portable MRI scanner approved by the FDA in 2020. Recently, MRI has been demonstrated also at ultra-low fields, i.e., in the microtesla-to-millitesla range, where sufficient signal quality is made possible by prepolarization (on the order of 10–100 mT) and by measuring the Larmor precession fields at about 100 microtesla with highly sensitive superconducting quantum interference devices (SQUIDs).
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.